Efficacy of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR 21L861Q mutation
10.3969/j.issn.1674-8115.2017.11.013
- VernacularTitle:EGFR-TKI对少见EGFR 21L861Q突变的晚期非小细胞肺癌患者的治疗效果
- Author:
guo Zhang HU
1
;
hui Shu CAO
;
Hua ZHONG
Author Information
1. 上海交通大学附属胸科医院呼吸内科
- Keywords:
non small cell lung cancer;
epidermal growth factor receptor-tyrosine kinase inhibitor;
EGFR uncommon mutations;
21L861Q
- From:
Journal of Shanghai Jiaotong University(Medical Science)
2017;37(11):1523-1527
- CountryChina
- Language:Chinese
-
Abstract:
Objective· To evaluate the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) in non small cell lung cancer (NSCLC)patients with uncommon EGFR 21L861Q mutation. Methods·Between June 2011 and Marth 2015,clinical data of 21 stageⅢB/ⅣNSCLC patients who received EGFR-TKI harboring uncommon 21L861Q mutation in EGFR at the Shanghai Chest Hospital were collected.Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS ) and overall survival (OS ) of the patients under TKI therapy were retrospectively analyzed. Results · ORR and DCR of the patients under TKIs therapy (first-line+second-line+third-line) were 42.9% and 66.7% respectively. PFS and OS of patients who received therapy that consisted of EGFR-TKIs(first-line+second-line+third-line)were 7.03 months(95% CI,5.50-8.69)and 22.80 months(95% CI,16.22-25.65). Conclusion·Our post-hoc analyses demonstrated that EGFR-TKIs showed activity in patients with uncommon EGFR 21L861Q-mutant NSCLC, less effective than in those with common mutations.
